Why Eli Lilly Topped the Market on Tuesday

Core Insights - Eli Lilly's stock rose over 3% following positive news regarding its obesity treatment, Zepbound, outperforming the S&P 500 index which fell by 0.2% [1] Group 1: Product Performance - Zepbound significantly reduced the risk of developing type 2 diabetes by 94% in vulnerable individuals, including those who are pre-diabetic or obese [2] - Patients treated with Zepbound experienced an average weight loss of nearly 23%, compared to only 2% for those on a placebo [2] Group 2: Analyst Recommendations - Wells Fargo has designated Eli Lilly as its top pick among large-cap pharmaceutical stocks, citing a strong pipeline and potential for growth [3] - The bank's analysts noted improvements in the supply chain and increasing international sales as factors contributing to Eli Lilly's attractiveness as an investment [3]